Early Phase III data suggest C5 complement inhibition may alter disease course in IgAN In a recent press release, AstraZeneca reported that Ultomiris (ravulizumab) has shown a statistically significant and…
Lynk Pharmaceuticals announced a significant development in its pipeline with the China National Medical Products Administration (NMPA) formally accepting the New Drug Application (NDA) for zemprocitinib capsules to treat moderate-to-severe…
As reported on BioPharmaDive, Roche is restarting efforts to get Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), approved in Europe by launching a new global Phase 3 trial…
As reported by Manila Times, Ocular Therapeutix has released additional one‑year results from its Phase 3 SOL‑1 trial evaluating AXPAXLI (formerly OTX‑TKI) for the treatment of neovascular age‑related macular degeneration…
Akebia Therapeutics has initiated clinical development of a new investigational therapy aimed at preventing or treating acute kidney injury (AKI) associated with cardiac surgery. The company announced that the first…
As reported on PharmaBiz, Amgen has announced encouraging topline results from a phase 3 clinical trial evaluating a subcutaneous formulation of Tepezza (teprotumumab-trbw) for adults with moderate-to-severe active thyroid eye…
As reported on PharmaBiz, a novel treatment strategy combining dual immunotherapy, targeted therapy, and transarterial chemoembolization (TACE) has demonstrated meaningful clinical benefit for patients with unresectable hepatocellular carcinoma (HCC), according…
As reported on BioPharmaDive, Amgen has announced positive Phase 3 results for a subcutaneous version of its thyroid eye disease (TED) therapy Tepezza, suggesting the new formulation performs similarly to…
As reported on FiercePharma, China-based biotech Dizal Pharmaceutical has reported a pivotal phase 3 success for its oral EGFR inhibitor Zegfrovy (sunvozertinib), marking a potential shift in first-line treatment for…
As reported on Healio, a novel biologic targeting two key angiogenic pathways has shown encouraging early results for the treatment of wet age-related macular degeneration (AMD). According to a recent…
In a recent press release, Structure Therapeutics has reported encouraging topline results from its Phase 2 ACCESS clinical program evaluating aleniglipron, an investigational once-daily oral small-molecule glucagon-like peptide‑1 (GLP‑1) receptor…
As reported by Pharma Times, Elevara Medicines has initiated a phase 2b clinical study evaluating ELV001, an investigational oral CDK4/6 inhibitor, in people with rheumatoid arthritis (RA) who continue to…
As reported on drugs.com, Bristol Myers Squibb (BMS) has announced encouraging interim results from the Phase 3 portion of the SUCCESSOR-2 clinical trial evaluating oral mezigdomide in patients with relapsed…
As covered on PharmaBiz, Roche has reported topline results from the phase III persevERA Breast Cancer study, which evaluated the oral selective oestrogen receptor degrader (SERD) giredestrant in combination with…
GlaxoSmithKline has achieved a significant regulatory milestone as China's National Medical Products Administration granted priority review status to linerixibat, an investigational treatment for cholestatic pruritus associated with primary biliary cholangitis.…
As reported on BioPharmaDive, Aardvark Therapeutics has halted dosing and enrollment in its late‑stage HERO trial for ARD‑101, a first‑in‑class treatment candidate for Prader–Willi syndrome (PWS), following the discovery of…
The landscape of advanced breast cancer treatment is shifting. Genentech's filing acceptance of giredestrant, an experimental oral medication, represents a pivotal moment for thousands of women grappling with a particularly…
As published in Sleep Review Magazine, Axsome Therapeutics has officially begun dosing patients in its Phase 3 CLARITY trial, a study designed to evaluate solriamfetol as a potential treatment for…
Eli Lilly is making strategic moves to expand its obesity medication Zepbound beyond weight management, demonstrating promising results when combined with its autoimmune therapeutic Taltz for treating patients with both…
AstraZeneca is navigating the final regulatory hurdles for an alternative delivery method of its lupus therapy. As reported by PharmaBiz.com, the company received a complete response letter from the FDA…
When ovarian cancer returns and becomes resistant to platinum-based treatments, patients face one of oncology's most difficult scenarios. As reported by Drugs.com, a new therapeutic approach is changing this reality.…
Cabaletta Bio has announced significant progress in its development of chimeric autoantibody receptor T cell (CAAR-T) therapies, marking a major milestone with the initiation of its first pivotal myositis trial…
Primary biliary cholangitis (PBC) represents a chronic, progressive autoimmune liver disease characterized by the destruction of small bile ducts, leading to cholestasis and potentially fatal complications. Affecting millions globally with…
Takeda Pharmaceutical has reached a significant milestone in the development of oveporexton (TAK-861), with the US Food and Drug Administration officially accepting and granting Priority Review status to the investigational…
Twelve‑month, real‑world data from a large U.S. registry suggest that faricimab provides effective, durable, and safe treatment for retinal vein occlusion (RVO), reinforcing findings from earlier clinical trials and its…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
